National Cancer Institute and National Institute on Drug Abuse Grant for Testing Tobacco Harm Reduction Products (R21)

Opportunity ID: 45374

General Information

Document Type: Grants Notice
Funding Opportunity Number: PA-09-047
Funding Opportunity Title: Testing Tobacco Products Promoted to Reduce Harm (R21)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.279 — Drug Abuse and Addiction Research Programs
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Feb 19, 2009
Last Updated Date:
Original Closing Date for Applications: May 07, 2012
Current Closing Date for Applications: May 07, 2012
Archive Date: Jun 07, 2012
Estimated Total Program Funding:
Award Ceiling:
Award Floor:

Eligibility

Eligible Applicants: Small businesses
City or township governments
Public and State controlled institutions of higher education
Private institutions of higher education
Special district governments
For profit organizations other than small businesses
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following:
Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; U.S. Territory or Possession.

Additional Information

Agency Name: National Institutes of Health
Description: Purpose. This funding opportunity announcement (FOA), issued by the National Cancer Institute (NCI) and the National Institute on Drug Abuse (NIDA), invites applications that propose multidisciplinary research on potential reduced-exposure tobacco products, both smoked and smokeless. The multidisciplinary studies can span basic, biological, behavioral, surveillance, and epidemiology research. The tobacco industry is currently promoting several new products with claims that they: a) are less either harmful or less addictive; and b) purportedly deliver lower amounts of toxic, carcinogenic, and/or addictive agents to the user compared with conventional products. However, to date, the scientific evidence is insufficient to evaluate whether these new products actually reduce the users exposure or risk for tobacco-related diseases. The overarching goal of this FOA is to determine whether potential reduced-exposure tobacco products provide a truly, less-harmful alternative to conventional tobacco products, both at the individual and population level.

Mechanism of Support. This FOA utilizes the NIH exploratory/developmental (R21) grant mechanism and runs in parallel with an FOA of identical scientific scope, PA-09-046, which uses the NIH Research Project Grant (R01) mechanism.

Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications; therefore, the anticipated number of awards is not known

Budget and Project Period. The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Research Plan Component Length: Items 2-5 of the PHS398 Research Plan component of the R21 application may not exceed 15 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21).

Eligible Institutions/Organizations. Institutions/organizations listed in Section III, 1.A. are eligible to apply.

Eligible Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Number of PDs/PIs. More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application.

Number of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct.

Resubmissions. Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement).See new NIH policy on resubmission (amended) applications (NOT-OD-09-003, NOT-OD-09-016).

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PA-09-047.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
ADOBE-FORMS-A Adobe-Forms-A PKG00010533 May 16, 2009 Feb 20, 2010 View
ADOBE-FORMS-B1 Supersedes ADOBE-FORMS-B PKG00022262 Nov 02, 2010 May 07, 2012 View
ADOBE-FORMS-B Use for submissions intended for due dates of January 25, 2010 and beyond PKG00015346 Dec 21, 2009 Nov 02, 2010 View

Package 1

Mandatory forms

45374 RR_SF424-1.1.pdf

45374 RR_KeyPersonExpanded-1.1.pdf

45374 RR_OtherProjectInfo-1.1.pdf

45374 RR_PerformanceSite-1.1.pdf

45374 PHS398_CoverPageSupplement-1.1.pdf

45374 PHS398_ResearchPlan-1.1.pdf

45374 PHS398_Checklist-1.1.pdf

Optional forms

45374 PHS398_CoverLetter-1.1.pdf

45374 PHS398_ModularBudget-1.1.pdf

45374 RR_Budget-1.1.pdf

45374 RR_SubawardBudget-1.2.pdf

Package 2

Mandatory forms

45374 RR_SF424_1_2-1.2.pdf

45374 RR_OtherProjectInfo_1_3-1.3.pdf

45374 RR_KeyPersonExpanded_1_2-1.2.pdf

45374 PerformanceSite_1_4-1.4.pdf

45374 PHS398_ResearchPlan_1_3-1.3.pdf

45374 PHS398_CoverPageSupplement_1_4-1.4.pdf

45374 PHS398_Checklist_1_3-1.3.pdf

Optional forms

45374 RR_Budget-1.1.pdf

45374 RR_SubawardBudget-1.2.pdf

45374 PHS_CoverLetter_1_2-1.2.pdf

45374 PHS398_ModularBudget-1.1.pdf

Package 3

Mandatory forms

45374 RR_SF424_1_2-1.2.pdf

45374 PerformanceSite_1_3-1.3.pdf

45374 RR_OtherProjectInfo_1_2-1.2.pdf

45374 RR_KeyPersonExpanded_1_2-1.2.pdf

45374 PHS398_CoverPageSupplement_1_4-1.4.pdf

45374 PHS398_ResearchPlan_1_3-1.3.pdf

45374 PHS398_Checklist_1_3-1.3.pdf

Optional forms

45374 PHS_CoverLetter_1_2-1.2.pdf

45374 PHS398_ModularBudget-1.1.pdf

45374 RR_Budget-1.1.pdf

45374 RR_SubawardBudget-1.2.pdf


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *